PGNX News and Press, Progenics Pharmaceuticals Inc. From 11/07/19

Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical Therapeutics AZEDRA Commercial Dosing Progresses in U.S. as New Technology Add-On Payment Became Effective Octo...

All Three Proxy Advisory Firms (Glass Lewis, ISS, and Egan Jones) Support Velan’s Case for Change and Recommend Stockholders Vote on the GREEN Consent Card Glass Lewis Recommends Stockholders Vote FOR Dr. Gérard Ber, Dr. Eric Ende, Heinz Mäusli and David Mims to Consti...

November 17 is the Only Deadline for Velan’s Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (...

NEW YORK, NY / ACCESSWIRE / November 2, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Innophos Holdings, Inc ( IPHS ) ("Innophos...

Progenics Pharmaceuticals ( PGNX +4.9% ) is sending a letter to shareholders urging them to revoke any consents they may have submitted to activist investor Velan Capital LP and to defer sending Velan any consents until they have the opportunity to read the preliminary S-4 detailing the ...

Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents Demanded by Velan Urges Shareholders to Review the S-4 Filing in Order to Make Ful...

ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by Revoking Consent to ALL of Velan’s Proposals NEW YOR...

Recommends Stockholders Vote FOR Dr. Gérard Ber, Dr. Eric Ende and David Mims Recommends Removal of CEO Mark Baker, Citing ‘Past Questionable Actions’ and ‘Poor Performance’ and Advises ‘DO NOT VOTE’ on the WHITE card Highlights Conce...

Today, Dr. Gérard Ber released an open letter to stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX) on behalf of himself and the four other fully-independent director candidates – Dr. Eric J. Ende, Ann MacDougal...

Progenics Has Again Resorted to False Information and Misleading Innuendo in Seemingly Desperate Attempt to Avoid Accountability and Deprive Stockholders of Chance to Realize Company’s Full Value Velan Purchased Progenics Stock Because of Conviction in Company’s Opportuni...